

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number
WO 02/051804 A1

- (51) International Patent Classification⁷: **C07D 207/34**
- (21) International Application Number: **PCT/EP01/15012**
- (22) International Filing Date:
19 December 2001 (19.12.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00811249.2 27 December 2000 (27.12.2000) EP
- (71) Applicant (*for all designated States except US*): **CIBA SPECIALTY CHEMICALS HOLDING INC.** [CH/CH]; Klybeckstrasse 141, CH-4057 Basel (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **VAN DER SCHAAF, Paul, Adriaan** [NL/CH]; Marsstrasse 17, CH-4123 Allschwil (CH). **BLATTER, Fritz** [CH/CH]; Oerinstrasse 67, CH-4153 Reinach (CH). **SZELAGIEWICZ, Martin** [CH/CH]; Christoph-Merian-Strasse 1, CH-4142 Münchenstein (CH). **SCHÖNING, Kai-Uwe** [DE/CH]; Am Rain 17, CH-5210 Windisch (CH).
- (74) Common Representative: **CIBA SPECIALTY CHEMICALS HOLDING INC.**; Patentabteilung, Klybeckstrasse 141, CH-4057 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CRYSTALLINE FORMS OF ATORVASTATIN

(57) Abstract: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.



WO 02/051804 A1


EXPRESS MAIL NO. EV545395338US
DOCKET NO. PC25264A

- 1 -

CRYSTALLINE FORMS OF ATORVASTATIN

The present invention is directed to crystalline forms of Atorvastatin calcium, processes for their preparation and pharmaceutical compositions comprising these crystalline forms.

The present invention relates to crystalline forms of Atorvastatin calcium. Atorvastatin calcium is known by the chemical name, [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1). Atorvastatin has the following formula:



Atorvastatin calcium is an orally-active hypocholesterolaemic, a liver-selective HMG-CoA reductase inhibitor. Processes for the preparation of Atorvastatin calcium are described in US-A-5,298,627, US-A-5,273,995 and WO-A-97/03960, and publications by P.L. Brower et al. in Tetrahedron Letters (1992), vol. 33, pages 2279-2282, K.L. Baumann et al. in Tetrahedron Letters (1992), vol. 33, pages 2283-2284 and A. Graul et al. in Drugs Future (1997), vol. 22, pages 956-968.

This calcium salt (2:1) is desirable since it enables Atorvastatin calcium to be conveniently formulated. The processes in the above mentioned patents and publications result in the preparation of amorphous Atorvastatin calcium.

The preparations of Atorvastatin calcium (2:1) described in WO-A-97/03958 and WO-A-97/03959 result in the isolation of crystalline Atorvastatin calcium with the polymorphic forms iii, and i, ii, and iv, respectively. However, there is still a need to produce Atorvastatin calcium in a reproducible, pure and crystalline form to enable formulations to meet exacting pharmaceutical requirements and specifications. Furthermore, it is economically desirable

that the product is stable for extended periods of time without the need for specialised storage conditions.

Surprisingly, there have now been found several novel crystalline forms of Atorvastatin calcium salt (2:1), herein designated as Form X, Form A, Form B1, Form B2, Form C, Form D and Form E. The novel forms of the present invention have a good thermal stability and/or good solubility characteristics.

Accordingly, the present invention is directed to the following polymorphic Forms X, A, B1, B2, C, D and E of Atorvastatin calcium salt (2:1).

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

27.9 (s), 20.9 (w), 18.9 (w), 16.1 (w), 11.1 (m), 10.5 (m), 9.1 (m), 5.53 (m), 5.07 (w), 4.77 (vw), 4.55 (m), 4.13 (w), 3.69 (w);

herein designated as Form X. Here and in the following the abbreviations in brackets mean: (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

31.0 (vw), 18.6 (m), 17.0 (w), 15.3 (vw), 12.8 (w), 11.2 (m), 9.6 (s), 9.3 (w), 8.6 (w), 7.4 (m), 6.5 (vw), 6.2 (vw), 5.47 (w), 5.21 (m), 4.64 (vs), 4.46 (s), 4.14 (m), 3.97 (m), 3.74 (m), 3.62 (vw), 3.38 (w), 3.10 (m),

herein designated as Form A.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

27.9 (m), 17.0 (m), 14.2 (w), 12.1 (vs), 10.1 (s), 8.6 (m), 7.1 (m), 6.1 (vw), 5.27 (m), 4.89 (m), 4.68 (m), 4.46 (m), 4.22 (m), 3.90 (w), 3.70 (w), 2.36 (vw),
herein designated as Form B1.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
28.1 (m), 17.2 (m), 14.0 (vw), 12.3 (s), 10.4 (s), 8.6 (m), 7.5 (w), 7.0 (m), 5.28 (m), 4.88 (m), 4.55 (m), 4.27 (m), 3.88 (vw), 3.73 (m),
herein designated as Form B2.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
28.8 (m), 24.0 (m), 17.1 (m), 11.3 (s), 9.8 (vw), 8.3 (w), 7.7 (vw), 6.9 (vw), 5.64 (vw), 5.21 (w), 4.59 (m), 4.39 (w), 4.16 (w), 3.70 (w),
herein designated as Form C.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
33.7 (w), 31.0 (m), 16.9 (m), 10.3 (s), 7.7 (w), 6.4 (vw), 4.84 (s),
herein designated as Form D.

A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
26.8 (s), 9.4 (w), 4.6 (m)
herein designated as Form E.

A discussion of the theory of X-ray powder diffraction patterns can be found in "X-ray diffraction procedures" by H.P. Klug and L.E. Alexander, J. Wiley, New York (1974).

Furthermore, the present invention is directed to processes for the preparation of Form X, Form A, Form B1, Form B2, Form C, Form D and Form E.

Form X can generally be prepared by drying of a solution of Atorvastatin calcium in an organic solvent. Examples of such organic solvents are alcohols, like methanol. Preferably, the solution in addition contains an organic non-solvent, like ethers, for example methyl tert.-butyl ether. Drying can be carried out at elevated temperature, or, preferably, at ambient temperature. If desired, during the preparation process seeding with Form X can be carried out.

Form A can generally be prepared by suspending Form X or the amorphous form in an organic solvent, like an alcohol, especially isopropanol. It is preferred that the organic solvent contains as a further solvent some water. The amount of water is preferably about 0.1 to 5%, preferably about 0.5 to 2%, especially about 1% by volume of the suspension. It is preferred that the suspension is treated at temperatures between 10 and 60°C (preferably 30 to 50°C), especially for a longer period of time, like 10 to 40 hours. If desired, during the preparation process seeding with Form A can be carried out.

Form A can also be prepared from Atorvastatin lacton upon subsequent reaction with NaOH to form Atorvastatin sodium followed by reaction with CaCl_2 in an organic solvent, like an alcohol, especially isopropanol. It is preferred that the organic solvent contains as a further solvent some water. The amount of water is preferably 0.1 to 10%. If desired, during the preparation process seeding with Form A can be carried out.

Form A can also be prepared directly from Atorvastatin lactone upon reaction with $\text{Ca}(\text{OH})_2$ in an organic solvent, like an alcohol, especially isopropanol. It is preferred that the organic solvent contains as a further solvent some water. The amount of water is preferably 0.1 to 10%. If desired, during the preparation process seeding with Form A can be carried out.

Form A can also be prepared by the reaction of Atorvastatin ammonium salt with $\text{Ca}(\text{II})$ -acetate in an organic solvent or a mixture of organic solvents, preferably a mixture of tert-butyl methyl ether (TBME) and isopropanol. The solid formed in this reaction is isolated by

filtration and then stirred as a suspension in an organic solvent, like an alcohol, especially isopropanol. It is preferred that the organic solvent contains as a further solvent some water. The amount of water is preferably 0.1 to 10%. It is preferred that the suspension is treated at temperatures between 10 and 60°C, especially for a longer period of time, like 10 to 60 hours. If desired, during the preparation process seeding with Form A can be carried out.

Form B1 can generally be prepared by suspending Form X or the amorphous form in acetonitrile containing a further organic solvent, like tetrahydrofuran. It is preferred that the suspension is treated at temperatures between 10 and 50°C (preferably ambient temperature), especially for a longer period of time, like 10 to 40 hours. If desired, during the preparation process seeding with Form B1 can be carried out.

Form B2 can generally be prepared by suspending Form X or the amorphous form in acetonitrile, preferably pure acetonitrile. It is preferred that the suspension is treated at temperatures between 10 and 50°C (preferably 30 to 50°C), especially for a longer period of time, like 10 to 40 hours. If desired, during the preparation process seeding with Form B2 can be carried out.

Form C can generally be prepared by suspending Form X or the amorphous form in a mixture of isopropanol and water, and treating the suspension at ambient temperature for a longer period of time, like 10 to 40 hours. If desired, during the preparation process seeding with Form C can be carried out.

Form D can generally be prepared by suspending Form X or the amorphous form in a mixture of ethanol and water at temperatures between about 20 to 60°C for a longer period of time, like 10 to 40 hours. If desired, during the preparation process seeding with Form D can be carried out.

Form E can generally be prepared by evaporation of a solution of any form of Atorvastatin, preferably Form X, in 2-butanone or from solvent mixtures of 2-butanone with heptane or ethylacetate or ternary mixtures of 2-butanone, heptane and ethylacetate. Evaporation is preferably carried out slowly, for example within 10 to 40 hours.

Another object of the present invention are pharmaceutical compositions comprising an effective amount of crystalline polymorphic Form X, Form A, Form B1, Form B2, Form C, Form D or Form E, and a pharmaceutically acceptable carrier.

The polymorphic forms may be used as single components or mixtures.

As to the novel polymorphic forms of Atorvastatin calcium it is preferred that these contain 25-100% by weight, especially 50-100% by weight, of at least one of the novel forms, based on the total amount of Atorvastatin calcium. Preferably, such an amount of the novel polymorphic forms of Atorvastatin calcium is 75-100% by weight, especially 90-100% by weight. Highly preferred is an amount of 95-100% by weight.

The following Examples illustrate the invention in more detail. Temperatures are given in degrees Celsius.

Example 1: Preparation of polymorphic Form X

Atorvastatin calcium Form X is prepared by dissolving 127 mg Atorvastatin calcium in a mixture of 2.0 ml methanol and 6.0 ml methyl tert.-butyl ether and drying of the solution at ambient temperature. Form X is characterized by a x-ray powder diffraction pattern as shown in Figure 1. Differential scanning calorimetry in a closed sample pan sealed after equilibrium under dry nitrogen for about 16 hours at ambient temperature shows a melting point of 168°C and an enthalpy of fusion of about 27 J/g (see Figure 6). Form X if stored under normal conditions contains about 4% of water.

Example 2: Preparation of polymorphic Form A

Form A is prepared by suspending 100 mg of Form X in 3.0 ml isopropanol together with 50 µl H₂O and stirring of this suspension at 40°C. After 9 hours an additional amount of 50 µl of water is added to the suspension and stirring is continued at 40°C for another 20 hours. The suspension is filtrated and crystalline Form A is obtained. Form A is characterized by a x-ray powder diffraction pattern as shown in Figure 2. Differential scanning calorimetry of Form A in a closed sample pan sealed after equilibration under dry nitrogen for about 16 hours at ambient temperature reveals a melting point of 179°C and an enthalpy of fusion of 53 J/g (see Figure 6).

In the above example it is also possible to start from the amorphous form of Atorvastatin calcium instead of Form X.

Example 3: Preparation of polymorphic Form B1

Atorvastatin calcium crystal Form B1 is prepared by suspending 145 mg of Atorvastatin calcium Form X in a mixture of 1.0 ml acetonitrile and 1.0 ml of tetrahydrofuran at ambient temperature. While the cap of the reaction vial is left open some of the tetrahydrofuran evaporates which leads to a slow reduction of the solubility of Atorvastatin calcium in the system. After 3.5 hours an additional amount of 1.0 ml of acetonitrile is added to the reaction container and stirring is continued for about 15 hours at ambient temperature. After filtration of the suspension crystal form B1 is obtained. Form B1 is characterized by a x-ray powder diffraction pattern as shown in Figure 3.

In the above example it is also possible to start from the amorphous form of Atorvastatin calcium instead of Form X.

Example 4: Preparation of polymorphic Form B2

Form B2 is prepared by suspending 117 mg of Atorvastatin calcium Form X in 2.0 ml of acetonitrile and stirring this suspension at 40°C for about 18 hours. In order to reduce the viscosity of the suspension 1.0 ml of acetonitrile is added at ambient temperature to this suspension after the end of the crystallization process. The obtained product is crystal Form B2 which is characterized by an x-ray powder diffraction pattern as shown in Figure 3.

In the above example it is also possible to start from the amorphous form of Atorvastatin calcium instead of Form X.

Example 5: Preparation of polymorphic Form C

Form C is prepared by suspending 120 mg of Atorvastatin calcium Form X in a mixture of 3.0 ml isopropanol and 1.0 ml water. After one hour of stirring at ambient temperature 2.0 ml water are added and stirring is continued for 15 hours at the same temperature. After filtration of the suspension crystal Form C is obtained which is characterized by the x-ray diffraction pattern as shown in Figure 4.

In the above example it is also possible to start from the amorphous form of Atorvastatin calcium instead of Form X.


Example 6: Preparation of polymorphic Form D

Form D is prepared by suspending 124 mg of Form X in 3.0 ml of ethanol and by stirring this suspension at ambient temperature. After about 2 hours a suspension of high viscosity is obtained and 1.0 ml of water are added to the suspension, which reduces the viscosity substantially. After addition of water, the temperature is slowly raised to 40°C and stirring is continued at 40°C for about 16 hours. After filtration of the suspension crystal Form D is obtained which is characterized by the x-ray diffraction pattern as shown in Figure 5.

In the above example it is also possible to start from the amorphous form of Atorvastatin calcium instead of Form X.

Example 7: Preparation of polymorphic Form E

60 mg of Atorvastatin Form X are dissolved in 2.0 ml 2-butanone (e.g. Fluka No. 04380) and then 2.0 ml of heptane (e.g. Fluka No. 51745) are added at ambient temperature. This mixture is heated to 50°C for a few minutes until all solid residues are dissolved. The mixture is then slowly cooled to 5°C and later equilibrated at ambient temperature. At ambient temperature the solvent is slowly evaporated within about 10 to 20 hours. After complete evaporation of the solvent Atorvastatin Form E is obtained as a solid residue. The X-ray diffraction pattern of Form E is shown in Figure 7.

Example 8:**a) Preparation of Atorvastatin lactone III:**

Diol acid I (5 g, 8.9 mmol) is dissolved in 10.7 ml ethanol and 5.6 ml 1.6 M NH_3 in ethanol is added at room temperature. The solution is being stirred over 15 to 30 minutes and the solvent is subsequently removed under reduced pressure to give a colorless or slightly beige foam (5.15 g, approximately 100% yield).

Ammonium salt II (23.91 g, 41.7 mmol) is dissolved in 115 ml acetic acid. The yellow solution is being stirred at 35°C for approximately 16 h. 200 ml dioxane are added twice and the mixture is being concentrated at 40°C and 35 mbar pressure, respectively. The residue is dissolved in 200 ml TBME and being washing with water and brine and dried over magnesium sulfate. Removal of the solvent affords 21.4 g (approx. 95 % yield) Atorvastatin lacton III.

b) Preparation of Atorvastatin calcium Form A starting from Atorvastatin lactone III:

Lacton III (20.6 g, 38.2 mmol) is dissolved in 757 ml 2-propanol/water (19:1) and 1.41 g (0.5 eq) calcium hydroxide is added. The turbid solution is stirred at 40°C for 3 d whereupon the

solution turns into a thick suspension. White crystals of form A are collected by filtration and being dried at 70 °C and 20 mbar pressure overnight. Yield: 19.0 g, 86 %.

Example 9: Preparation of Atorvastatin calcium Form A starting from Atorvastatin ammonium salt II:

Ammonium salt II (2 g, 3.5 mmol) is dissolved in 20 ml TBME/isopropanol (1:2) and a solution of calciumacetat hydrate (0.5 eq) is added dropwise at room temperature. The precipitated calcium salt is collected by filtration and dried at 70 °C and 20 mbar. (Yield 1.6 g, approx. 80 %.) The obtained powder is subsequently being stirred in 58 ml 2-propanol/water (19:1) at 40 °C and seeded with 5 % crystals of form A. After 4 d Atorvastatin Calcium form A can be collected by filtration (yield 1.5 g, 91 %).

Brief description of the drawings

Figure 1 is a characteristic X-ray powder diffraction pattern for Form X.

Figure 2 is a characteristic X-ray powder diffraction pattern for Form A.

Figure 3 are characteristic X-ray powder diffraction patterns for Form B1 and B2.

Figure 4 is a characteristic X-ray powder diffraction pattern for Form C.

Figure 5 is a characteristic X-ray powder diffraction pattern for Form D.

Figure 6 are characteristic Differential Scanning Calorimetry (DSC) scans of Form A and Form X.

Figure 7 is a characteristic X-ray powder diffraction pattern for Form E.

Claims

1. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
27.9 (s), 20.9 (w), 18.9 (w), 16.1 (w), 11.1 (m), 10.5 (m), 9.1 (m), 5.53 (m), 5.07 (w), 4.77 (vw), 4.55 (m), 4.13 (w), 3.69 (w);
wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.
2. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
31.0 (vw), 18.6 (m), 17.0 (w), 15.3 (vw), 12.8 (w), 11.2 (m), 9.6 (s), 9.3 (w), 8.6 (w), 7.4 (m), 6.5 (vw), 6.2 (vw), 5.47 (w), 5.21 (m), 4.64 (vs), 4.46 (s), 4.14 (m), 3.97 (m), 3.74 (m), 3.62 (vw), 3.38 (w), 3.10 (m);
wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.
3. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at
27.9 (m), 17.0 (m), 14.2 (w), 12.1 (vs), 10.1 (s), 8.6 (m), 7.1 (m), 6.1 (vw), 5.27 (m), 4.89 (m), 4.68 (m), 4.46 (m), 4.22 (m), 3.90 (w), 3.70 (w), 2.36 (vw);
wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.
4. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

28.1 (m), 17.2 (m), 14.0 (vw), 12.3 (s), 10.4 (s), 8.6 (m), 7.5 (w), 7.0 (m), 5.28 (m), 4.88 (m), 4.55 (m), 4.27 (m), 3.88 (vw), 3.73 (m);

wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.

5. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

28.8 (m), 24.0 (m), 17.1 (m), 11.3 (s), 9.8 (vw), 8.3 (w), 7.7 (vw), 6.9 (vw), 5.64 (vw), 5.21 (w), 4.59 (m), 4.39 (w), 4.16 (w), 3.70 (w);

wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.

6. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

33.7 (w), 31.0 (m), 16.9 (m), 10.3 (s), 7.7 (w), 6.4 (vw), 4.84 (s);

wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; (vw) = very weak intensity.

7. A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt which exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (Å) at

26.8 (s), 9.4 (w), 4.6 (m);


wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity.

8. A process for the preparation of a crystalline polymorph according to claim 1, which comprises drying a solution of Atorvastatin calcium in an organic solvent, with or without presence of a non-solvent.

9. A process for the preparation of a crystalline polymorph according to claim 2, which comprises suspending a crystalline polymorph according claim 1 or amorphous Atorvastatin calcium in an alcohol containing a small amount of water and treating the suspension at a temperature between 10 and 60°C.
10. A process for the preparation of a crystalline polymorph according to claim 3, which comprises suspending a crystalline polymorph according to claim 1 or the amorphous form of Atorvastatin calcium in acetonitrile containing a further organic solvent, and treating the suspension at temperatures between 10 and 50°C.
11. A process for the preparation of a crystalline polymorph according to claim 4, which comprises suspending a crystalline polymorph according to claim 1 or the amorphous form of Atorvastatin calcium in acetonitrile, and treating the suspension at temperatures between 10 and 50°C.
12. A process for the preparation of a crystalline polymorph according to claim 5, which comprises suspending a crystalline polymorph according to claim 1 or the amorphous form of Atorvastatin calcium in a mixture of isopropanol and water and treating the suspension at ambient temperature.
13. A process for the preparation of a crystalline polymorph according to claim 6, which comprises suspending a crystalline polymorph according to claim 1 or the amorphous form of Atorvastatin calcium in a mixture of ethanol and water and treating the suspension at temperatures between 20 to 60°C.
14. A process for the preparation of a crystalline polymorph according to claim 7, which comprises dissolving a crystalline polymorph according to claim 1 or the amorphous form of Atorvastatin calcium in a mixture of 2-butanone and ethyl acetate and/or heptane and evaporating of the solvent.
15. A process for the preparation of a crystalline polymorph according to claim 2, which comprises treating a solution of Atorvastatin lactone in a mixture of isopropanol and water with calcium hydroxide.

16. A pharmaceutical composition comprising an effective amount of a crystalline polymorphic form according to any of claims 1 to 7, and a pharmaceutically acceptable carrier.

Fig. 1



2/7

Fig. 2




Fig. 3





Fig. 4



5/7

Fig. 5




Fig. 6





Fig. 7



INTERNATIONAL SEARCH REPORT

In ☐ National Application No
PCT/EP01/15012A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 03959 A (WARNER LAMBERT CO ;BRIGGS CHRISTOPHER A (US); JENNINGS REX ALLEN () 6 February 1997 (1997-02-06) cited in the application claims 1-29	1-16
X	WO 97 03958 A (WARNER LAMBERT CO ;MCKENZIE ANN T (US)) 6 February 1997 (1997-02-06) cited in the application claims 1-9	1-16
P,X	WO 01 36384 A (TEVA PHARMA ;AYALON ARI (IL); NIDDAM VALERIE (IL); ROYTBAT SOFIA) 25 May 2001 (2001-05-25) claims 1-16	1-16

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

8 April 2002

Date of mailing of the international search report

15/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP01/15012

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 01 44181 A (TULLY WILLIAM ;CONNELL JOHN O (IE); MADIGAN EVELYN (IE); WARNER LA) 21 June 2001 (2001-06-21) claims 1-5</p> <p>-----</p>	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP01/15012

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9703959	A	06-02-1997	AT 208375 T	15-11-2001
			AU 725424 B2	12-10-2000
			AU 6484296 A	18-02-1997
			BG 102187 A	30-10-1998
			BR 9609872 A	23-03-1999
			CA 2220018 A1	06-02-1997
			CN 1190955 A	19-08-1998
			CZ 9800121 A3	14-10-1998
			DE 69616808 D1	13-12-2001
			DK 848705 T3	04-02-2002
			EE 9800015 A	17-08-1998
			EP 1148049 A1	24-10-2001
			EP 0848705 A1	24-06-1998
			HR 960339 A1	30-04-1998
			HU 9900678 A2	28-07-1999
			IL 122118 A	14-07-1999
			JP 11509230 T	17-08-1999
			NO 980207 A	16-01-1998
			PL 324496 A1	25-05-1998
			SK 6298 A3	07-10-1998
			WO 9703959 A1	06-02-1997
			US 5969156 A	19-10-1999
WO 9703958	A	06-02-1997	AT 207465 T	15-11-2001
			AU 725368 B2	12-10-2000
			AU 6484196 A	18-02-1997
			BG 102186 A	30-10-1998
			BR 9610567 A	06-07-1999
			CA 2220458 A1	06-02-1997
			CN 1190957 A , B	19-08-1998
			CZ 9800123 A3	17-06-1998
			DE 69616358 D1	29-11-2001
			DK 848704 T3	04-02-2002
			EE 9800016 A	17-08-1998
			EP 0848704 A1	24-06-1998
			HR 960313 A1	30-04-1998
			HU 9901687 A2	28-10-1999
			IL 122162 A	14-07-1999
			JP 11509229 T	17-08-1999
			NO 980208 A	16-01-1998
			PL 324532 A1	08-06-1998
			SK 5998 A3	06-05-1998
			TW 401399 B	11-08-2000
			WO 9703958 A1	06-02-1997
			US 6121461 A	19-09-2000
WO 0136384	A	25-05-2001	AU 1617301 A	30-05-2001
			WO 0136384 A1	25-05-2001
WO 0144181	A	21-06-2001	AU 2214301 A	25-06-2001
			WO 0144181 A1	21-06-2001